

20 November 2019 EMA/HMPC/554043/2018 Committee on Herbal Medicinal Products (HMPC)

# European Union herbal monograph on *Herniaria glabra* L., *H. hirsuta* L., *H. incana* Lam., herba

Draft

Initial assessment	
Discussion in Working Party on European Union monographs and	September 2018
European Union list (MLWP) and Committee on Herbal Medicinal	May 2019
Products (HMPC)	July 2019
	November 2019
Adoption by HMPC for release for consultation	20 November 2019
End of consultation (deadline for comments). Comments should be	15 March 2020
provided using this template to hmpc.secretariat@ema.europa.eu>	15 March 2020
Re-discussion in HMPC/MLWP	
Adoption by HMPC	

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs;
	traditional use; Herniaria glabra L., H. hirsuta L., H. incana Lam., herba;
	Herniariae herba; rupturewort

BG (bulgarski): Изсипливче, стрък	LT (lietuvių kalba): Skleistenių žolė
CS (čeština): průtržníková nať	LV (latviešu valoda): trūkumzālītes laksti
DA (dansk): Brudurt	MT (Malti): Ħaxixa tal-Ħerniarja
DE (Deutsch): Bruchkraut	NL (Nederlands): Breukkruid, kruid
EL (elliniká):	PL (polski): ziele połonicznika
EN (English): rupturewort	PT (português):
ES (español): Herniaria, parte aérea de	RO (română): iarbă de feciorică
ET (eesti keel):	SK (slovenčina): vňať prietržníka
FI (suomi): tyräruoho, verso	SL (slovenščina):
FR (français): herniaire	SV (svenska): knytling, ört
HR (hrvatski): kilavičina zelen	IS (íslenska):
HU (magyar): porcikafű	NO (norsk):
IT (italiano):	

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.

# European Union herbal monograph on *Herniaria glabra* L., *H. hirsuta* L., *H. incana* Lam., herba

# 1. Name of the medicinal product

To be specified for the individual finished product.

# 1. Qualitative and quantitative composition 1, 2

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC
	<i>Herniaria glabra</i> L., <i>H. hirsuta</i> L., <i>H. incana</i> Lam., herba (rupturewort) or a mixture of them
	i) Herbal substance
	Not applicable
	ii) Herbal preparations
	Comminuted herbal substance

#### 2. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

### 3. Clinical particulars

#### 3.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints. The product is a traditional herbal medicinal

<sup>&</sup>lt;sup>1</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>&</sup>lt;sup>2</sup> The material complies with the Monograph in the Austrian Pharmacopoeia (monograph ÖAB 2010/056)

Well-established use	Traditional use
	product for use in the specified indication exclusively based upon long-standing use.

#### 3.2. Posology and method of administration<sup>3</sup>

Well-established use	Traditional use
	Posology
	Adults and Elderly Herbal tea: 1.5-3 g of comminuted herbal substance in 150 ml of boiling water as a herbal infusion or in 150 ml water as decoction 3-5 times daily.
	Maximum daily dose: 10 g.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use

#### 3.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.
	Conditions where a reduced fluid intake is recommended (e.g. severe cardiac or renal disease).

#### 3.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.

<sup>&</sup>lt;sup>3</sup> For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	To ensure an increase of the amount of urine, adequate fluid intake is required during the treatment. If urinary tract complaints worsen and symptoms such as fever, dysuria, spasm, or blood in the urine occur during the use of medicinal product, a doctor or a qualified health care practitioner should be consulted.

# 3.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

#### 3.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

#### 3.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 3.8. Undesirable effects

Well-established use	Traditional use
	None known
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

#### 3.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

# 4. Pharmacological properties

#### 4.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

#### 4.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

#### 4.3. Preclinical safety data

Well-established use	Traditional use
	<ul> <li>Not required as per Article 16c(1)(a)(iii) of</li> <li>Directive 2001/83/EC, unless necessary for the safe use of the product.</li> <li>Adequate tests on genotoxicity have not been performed.</li> <li>Tests on reproductive toxicity and carcinogenicity have not been performed.</li> </ul>

### 5. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable

# 6. Date of compilation/last revision

20 November 2019